{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:39:58Z","timestamp":1792456798077,"version":"4.5.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":65,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172827"],"award-info":[{"award-number":["82172827"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172835"],"award-info":[{"award-number":["82172835"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Breast cancer remains a major global health challenge for women. Chemotherapy resistance is a key driver of breast cancer recurrence and metastasis. Although meiotic nuclear division 1 (MND1) has been characterized as an oncogenic factor involved in mitotic progression and homologous recombination (HR), the precise molecular mechanisms underlying these MND1-mediated processes remain unclear. The expression of MND1 in breast cancer cell lines was evaluated by RT-qPCR and western blot. The functional effects of MND1 were assessed through a series of in vitro and in vivo assays, including cell proliferation assays, determination of resistance curves, DNA damage detection and flow cytometry. Protein interactions among MND1, RAD51, and USP5 were determined by co-immunoprecipitation assays. Transcriptional regulation of MND1 by E2F1 and promoter methylation status were analyzed using luciferase reporter assays and bisulfite sequencing PCR, respectively. We demonstrated that MND1 is upregulated in breast cancer and associated with cancer progression and cisplatin resistance. Mechanistically, MND1 promotes HR repair by recruiting USP5 to deubiquitinate and stabilize RAD51. Furthermore, E2F1 induces promoter hypomethylation and transcriptionally activates MND1 by binding to its promoter. Our findings establish a role for MND1 in regulating chemosensitivity and provide new insights into relevant gene interaction networks. The identified E2F1\/MND1\/USP5\/RAD51 feedback loop underscores the potential of MND1 as a therapeutic target for breast cancer.<\/jats:p>","DOI":"10.1038\/s41419-026-08912-w","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T16:37:16Z","timestamp":1780504636000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["MND1 reduces breast cancer chemosensitivity by promoting RAD51-mediated homologous recombination repair"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8891-4485","authenticated-orcid":false,"given":"Hao-Ran","family":"Yue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Hao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Meng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Yue","family":"Hai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Bo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0648-4897","authenticated-orcid":false,"given":"Xiao-Feng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao-Hui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2053-9866","authenticated-orcid":false,"given":"Yue","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9547-6735","authenticated-orcid":false,"given":"Jie","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"8912_CR1","first-page":"477","volume":"74","author":"AN Giaquinto","year":"2024","unstructured":"Giaquinto AN, Sung H, Newman LA, Freedman RA, Smith RA, Star J, et al. Breast cancer statistics 2024. CA Cancer J Clin. 2024;74:477\u201395.","journal-title":"CA Cancer J Clin"},{"key":"8912_CR2","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1016\/S0140-6736(05)66546-4","volume":"365","author":"U Veronesi","year":"2005","unstructured":"Veronesi U, Boyle P, Goldhirsch A, Orecchia R, Viale G. Breast cancer. Lancet. 2005;365:1727\u201341.","journal-title":"Lancet"},{"key":"8912_CR3","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.canlet.2020.10.016","volume":"497","author":"X Bai","year":"2021","unstructured":"Bai X, Ni J, Beretov J, Graham P, Li Y. Triple-negative breast cancer therapeutic resistance: where is the Achilles\u2019 heel? Cancer Lett. 2021;497:100\u201311.","journal-title":"Cancer Lett"},{"key":"8912_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104806","volume":"156","author":"P Jabbarzadeh Kaboli","year":"2020","unstructured":"Jabbarzadeh Kaboli P, Salimian F, Aghapour S, Xiang S, Zhao Q, Li M, et al. Akt-targeted therapy as a promising strategy to overcome drug resistance in breast cancer\u2014a comprehensive review from chemotherapy to immunotherapy. Pharm Res. 2020;156:104806.","journal-title":"Pharm Res"},{"key":"8912_CR5","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1038\/s43018-022-00466-y","volume":"3","author":"A Shahbandi","year":"2022","unstructured":"Shahbandi A, Chiu FY, Ungerleider NA, Kvadas R, Mheidly Z, Sun MJS, et al. Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80. Nat Cancer. 2022;3:1513\u201333.","journal-title":"Nat Cancer"},{"key":"8912_CR6","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","volume":"392","author":"KL Jhaveri","year":"2025","unstructured":"Jhaveri KL, Neven P, Casalnuovo ML, Kim SB, Tokunaga E, Aftimos P, et al. Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med. 2025;392:1189\u2013202.","journal-title":"N Engl J Med"},{"key":"8912_CR7","doi-asserted-by":"publisher","first-page":"8550","DOI":"10.1093\/nar\/gkad561","volume":"51","author":"W Lee","year":"2023","unstructured":"Lee W, Iwasaki H, Tsubouchi H, Li HW. Hop2-Mnd1 and Swi5-Sfr1 stimulate Dmc1 filament assembly using distinct mechanisms. Nucleic Acids Res. 2023;51:8550\u201362.","journal-title":"Nucleic Acids Res"},{"key":"8912_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53641-3","volume":"15","author":"JC Peng","year":"2024","unstructured":"Peng JC, Chang HY, Sun YL, Prentiss M, Li HW, Chi P. Hop2-Mnd1 functions as a DNA sequence fidelity switch in Dmc1-mediated DNA recombination. Nat Commun. 2024;15:9266.","journal-title":"Nat Commun"},{"key":"8912_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112484","volume":"42","author":"A Zelceski","year":"2023","unstructured":"Zelceski A, Francica P, Lingg L, Mutlu M, Stok C, Liptay M, et al. MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells. Cell Rep. 2023;42:112484.","journal-title":"Cell Rep"},{"key":"8912_CR10","doi-asserted-by":"crossref","unstructured":"Zhao Z, Zou Y, Lv Q, Wu C, Tang K, Dai F, et al. MND1 promotes the proliferation of prostate cancer cell via the CCNB1\/p53 signaling pathway. Curr Cancer Drug Targets. 2025;25:1158\u201369.","DOI":"10.2174\/0115680096391591250506064859"},{"key":"8912_CR11","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/cac2.12155","volume":"41","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Shi R, Bai Y, Meng L, Hu J, Zhu H, et al. Meiotic nuclear divisions 1 (MND1) fuels cell cycle progression by activating a KLF6\/E2F1 positive feedback loop in lung adenocarcinoma. Cancer Commun. 2021;41:492\u2013510.","journal-title":"Cancer Commun"},{"key":"8912_CR12","doi-asserted-by":"publisher","first-page":"4721","DOI":"10.2147\/JIR.S458832","volume":"17","author":"W Zhang","year":"2024","unstructured":"Zhang W, Xiao Y, Zhu X, Zhang Y, Xiang Q, Wu S, et al. Integrative pan-cancer analysis reveals the oncogenic role of MND1 and validation of MND1\u2019s role in breast cancer. J Inflamm Res. 2024;17:4721\u201346.","journal-title":"J Inflamm Res"},{"key":"8912_CR13","doi-asserted-by":"publisher","first-page":"7416","DOI":"10.18632\/aging.204280","volume":"14","author":"J Fang","year":"2022","unstructured":"Fang J, Zhen J, Gong Y, Ke Y, Fu B, Jiang Y, et al. MND1 functions as a potential prognostic biomarker associated with cell cycle and immune infiltration in kidney renal clear cell carcinoma. Aging. 2022;14:7416\u201342.","journal-title":"Aging"},{"key":"8912_CR14","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41392-020-0150-x","volume":"5","author":"RX Huang","year":"2020","unstructured":"Huang RX, Zhou PK. DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. Signal Transduct Target Ther. 2020;5:60.","journal-title":"Signal Transduct Target Ther"},{"key":"8912_CR15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1146\/annurev.biochem.73.011303.073723","volume":"73","author":"A Sancar","year":"2004","unstructured":"Sancar A, Lindsey-Boltz LA, Unsal-Ka\u00e7maz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem. 2004;73:39\u201385.","journal-title":"Annu Rev Biochem"},{"key":"8912_CR16","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1016\/j.celrep.2020.01.052","volume":"30","author":"MY Cai","year":"2020","unstructured":"Cai MY, Dunn CE, Chen W, Kochupurakkal BS, Nguyen H, Moreau LA, et al. Cooperation of the ATM and Fanconi anemia\/BRCA pathways in double-strand break end resection. Cell Rep. 2020;30:2402\u201315.e5.","journal-title":"Cell Rep"},{"key":"8912_CR17","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.molcel.2020.04.035","volume":"78","author":"JM Cleary","year":"2020","unstructured":"Cleary JM, Aguirre AJ, Shapiro GI, D\u2019Andrea AD. Biomarker-guided development of DNA repair inhibitors. Mol Cell. 2020;78:1070\u201385.","journal-title":"Mol Cell"},{"key":"8912_CR18","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.canlet.2021.10.001","volume":"524","author":"J Zhang","year":"2022","unstructured":"Zhang J, Wu Q, Zhu L, Xie S, Tu L, Yang Y, et al. SERPINE2\/PN-1 regulates the DNA damage response and radioresistance by activating ATM in lung cancer. Cancer Lett. 2022;524:268\u201383.","journal-title":"Cancer Lett"},{"key":"8912_CR19","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/cpr.12203","volume":"48","author":"N Liang","year":"2015","unstructured":"Liang N, Zhong R, Hou X, Zhao G, Ma S, Cheng G, et al. Ataxia-telangiectasia mutated (ATM) participates in the regulation of ionizing radiation-induced cell death via MAPK14 in lung cancer H1299 cells. Cell Prolif. 2015;48:561\u201372.","journal-title":"Cell Prolif"},{"key":"8912_CR20","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13046-025-03357-z","volume":"44","author":"X Liu","year":"2025","unstructured":"Liu X, Zhang S, An Y, Xu B, Yan G, Sun M. USP10\/XAB2\/ANXA2 axis promotes DNA damage repair to enhance chemoresistance to oxaliplatin in colorectal cancer. J Exp Clin Cancer Res. 2025;44:94.","journal-title":"J Exp Clin Cancer Res"},{"key":"8912_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04672-5","volume":"13","author":"Y Sun","year":"2022","unstructured":"Sun Y, Dong D, Xia Y, Hao L, Wang W, Zhao C. YTHDF1 promotes breast cancer cell growth, DNA damage repair and chemoresistance. Cell Death Dis. 2022;13:230.","journal-title":"Cell Death Dis"},{"key":"8912_CR22","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.7150\/thno.46460","volume":"11","author":"H Wang","year":"2021","unstructured":"Wang H, Guo S, Kim SJ, Shao F, Ho JWK, Wong KU, et al. Cisplatin prevents breast cancer metastasis through blocking early EMT and retards cancer growth together with paclitaxel. Theranostics. 2021;11:2442\u201359.","journal-title":"Theranostics"},{"key":"8912_CR23","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13046-015-0275-x","volume":"34","author":"D Westover","year":"2015","unstructured":"Westover D, Li F. New trends for overcoming ABCG2\/BCRP-mediated resistance to cancer therapies. J Exp Clin Cancer Res. 2015;34:159.","journal-title":"J Exp Clin Cancer Res"},{"key":"8912_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217309","volume":"607","author":"XD Dong","year":"2024","unstructured":"Dong XD, Zhang M, Teng QX, Lei ZN, Cai CY, Wang JQ, et al. Mobocertinib antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells: In vitro and in vivo studies. Cancer Lett. 2024;607:217309.","journal-title":"Cancer Lett"},{"key":"8912_CR25","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/nature08467","volume":"461","author":"SP Jackson","year":"2009","unstructured":"Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009;461:1071\u20138.","journal-title":"Nature"},{"key":"8912_CR26","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.canlet.2014.01.005","volume":"346","author":"NA Bowden","year":"2014","unstructured":"Bowden NA. Nucleotide excision repair: why is it not used to predict response to platinum-based chemotherapy? Cancer Lett. 2014;346:163\u201371.","journal-title":"Cancer Lett"},{"key":"8912_CR27","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1093\/annonc\/mdy099","volume":"29","author":"C Cruz","year":"2018","unstructured":"Cruz C, Castroviejo-Bermejo M, Guti\u00e9rrez-Enr\u00edquez S, Llop-Guevara A, Ibrahim YH, Gris-Oliver A, et al. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. Ann Oncol. 2018;29:1203\u201310.","journal-title":"Ann Oncol"},{"key":"8912_CR28","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.it.2021.02.001","volume":"42","author":"TJ Weitering","year":"2021","unstructured":"Weitering TJ, Takada S, Weemaes CMR, van Schouwenburg PA, van der Burg M. ATM: Translating the DNA Damage Response to Adaptive Immunity. Trends Immunol. 2021;42:350\u201365.","journal-title":"Trends Immunol"},{"key":"8912_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02449-w","volume":"24","author":"Q Zhou","year":"2025","unstructured":"Zhou Q, Wang Q, Duan Y, Zhang C, Liu T, Liu H, et al. BRD9-p53-E2F1 circuit orchestrates cell growth and DNA damage repair in gastric cancer. Mol Cancer. 2025;24:239.","journal-title":"Mol Cancer"},{"key":"8912_CR30","doi-asserted-by":"publisher","first-page":"671","DOI":"10.15252\/embr.201541455","volume":"17","author":"JK Ahlskog","year":"2016","unstructured":"Ahlskog JK, Larsen BD, Achanta K, S\u00f8rensen CS. ATM\/ATR-mediated phosphorylation of PALB2 promotes RAD51 function. EMBO Rep. 2016;17:671\u201381.","journal-title":"EMBO Rep"},{"key":"8912_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188597","volume":"1876","author":"A Demeyer","year":"2021","unstructured":"Demeyer A, Benhelli-Mokrani H, Ch\u00e9nais B, Weigel P, Fleury F. Inhibiting homologous recombination by targeting RAD51 protein. Biochim Biophys Acta Rev Cancer. 2021;1876:188597.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"8912_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56564-9","volume":"16","author":"N Shao","year":"2025","unstructured":"Shao N, Xi L, Lv Y, Idris M, Zhang L, Cao Y, et al. USP5 stabilizes YTHDF1 to control cancer immune surveillance through mTORC1-mediated phosphorylation. Nat Commun. 2025;16:1313.","journal-title":"Nat Commun"},{"key":"8912_CR33","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7150\/thno.27654","volume":"9","author":"J Meng","year":"2019","unstructured":"Meng J, Ai X, Lei Y, Zhong W, Qian B, Qiao K, et al. USP5 promotes epithelial-mesenchymal transition by stabilizing SLUG in hepatocellular carcinoma. Theranostics. 2019;9:573\u201387.","journal-title":"Theranostics"},{"key":"8912_CR34","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/s13046-025-03548-8","volume":"44","author":"Z Qian","year":"2025","unstructured":"Qian Z, Jiang Y, Cai Y, Gao E, Wang C, Dong J, et al. FASN inhibits ferroptosis in breast cancer via USP5 palmitoylation-dependent regulation of GPX4 deubiquitination. J Exp Clin Cancer Res. 2025;44:289.","journal-title":"J Exp Clin Cancer Res"},{"key":"8912_CR35","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/s41388-023-02936-8","volume":"43","author":"H Cai","year":"2024","unstructured":"Cai H, Ke ZB, Chen JY, Li XD, Zhu JM, Xue YT, et al. Ubiquitin-specific protease 5 promotes bladder cancer progression through stabilizing Twist1. Oncogene. 2024;43:703\u201313.","journal-title":"Oncogene"},{"key":"8912_CR36","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1158\/0008-5472.CAN-23-0015","volume":"83","author":"S Yu","year":"2023","unstructured":"Yu S, Wang Y, Gong X, Fan Z, Wang Z, Liang Z, et al. LncRNA AGPG confers endocrine resistance in breast cancer by promoting E2F1 activity. Cancer Res. 2023;83:3220\u201336.","journal-title":"Cancer Res"},{"key":"8912_CR37","doi-asserted-by":"publisher","first-page":"3672","DOI":"10.1158\/1078-0432.CCR-08-2343","volume":"15","author":"GW Woodfield","year":"2009","unstructured":"Woodfield GW, Hitchler MJ, Chen Y, Domann FE, Weigel RJ. Interaction of TFAP2C with the estrogen receptor-alpha promoter is controlled by chromatin structure. Clin Cancer Res. 2009;15:3672\u20139.","journal-title":"Clin Cancer Res"},{"key":"8912_CR38","first-page":"2279","volume":"55","author":"AT Ferguson","year":"1995","unstructured":"Ferguson AT, Lapidus RG, Baylin SB, Davidson NE. Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res. 1995;55:2279\u201383.","journal-title":"Cancer Res"},{"key":"8912_CR39","first-page":"7025","volume":"61","author":"X Yang","year":"2001","unstructured":"Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG, Davidson NE. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res. 2001;61:7025\u20139.","journal-title":"Cancer Res"},{"key":"8912_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107534","volume":"210","author":"R Roskoski Jr","year":"2024","unstructured":"Roskoski R Jr. Targeted and cytotoxic inhibitors used in the treatment of breast cancer. Pharm Res. 2024;210:107534.","journal-title":"Pharm Res"},{"key":"8912_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-1248-8","volume":"10","author":"M Yan","year":"2019","unstructured":"Yan M, Wang J, Ren Y, Li L, He W, Zhang Y, et al. Over-expression of FSIP1 promotes breast cancer progression and confers resistance to docetaxel via MRP1 stabilization. Cell Death Dis. 2019;10:204.","journal-title":"Cell Death Dis"},{"key":"8912_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114346","volume":"237","author":"IF Zattoni","year":"2022","unstructured":"Zattoni IF, Delabio LC, Dutra JP, Kita DH, Scheiffer G, Hembecker M, et al. Targeting breast cancer resistance protein (BCRP\/ABCG2): functional inhibitors and expression modulators. Eur J Med Chem. 2022;237:114346.","journal-title":"Eur J Med Chem"},{"key":"8912_CR43","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1146\/annurev-pharmtox-011613-135959","volume":"54","author":"SP Cole","year":"2014","unstructured":"Cole SP. Targeting multidrug resistance protein 1 (MRP1, ABCC1): past, present, and future. Annu Rev Pharmacol Toxicol. 2014;54:95\u2013117.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"8912_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-023-03077-4","volume":"23","author":"X Hu","year":"2023","unstructured":"Hu X, Zhou S, Li H, Wu Z, Wang Y, Meng L, et al. FOXA1\/MND1\/TKT axis regulates gastric cancer progression and oxaliplatin sensitivity via PI3K\/AKT signaling pathway. Cancer Cell Int. 2023;23:234.","journal-title":"Cancer Cell Int"},{"key":"8912_CR45","doi-asserted-by":"publisher","first-page":"4959","DOI":"10.2147\/IJGM.S354826","volume":"15","author":"Z Bao","year":"2022","unstructured":"Bao Z, Cheng J, Zhu J, Ji S, Gu K, Zhao Y, et al. Using weighted gene co-expression network analysis to identify increased MND1 expression as a predictor of poor breast cancer survival. Int J Gen Med. 2022;15:4959\u201374.","journal-title":"Int J Gen Med"},{"key":"8912_CR46","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","volume":"19","author":"G Bianchini","year":"2022","unstructured":"Bianchini G, De Angelis C, Licata L, Gianni L. Treatment landscape of triple-negative breast cancer\u2014expanded options, evolving needs. Nat Rev Clin Oncol. 2022;19:91\u2013113.","journal-title":"Nat Rev Clin Oncol"},{"key":"8912_CR47","doi-asserted-by":"publisher","first-page":"4995","DOI":"10.1158\/1078-0432.CCR-22-0482","volume":"28","author":"O Gluz","year":"2022","unstructured":"Gluz O, Nitz U, Kolberg-Liedtke C, Prat A, Christgen M, Kuemmel S, et al. De-escalated neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): impact of molecular markers and final survival analysis of the WSG-ADAPT-TN trial. Clin Cancer Res. 2022;28:4995\u20135003.","journal-title":"Clin Cancer Res"},{"key":"8912_CR48","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41388-024-03227-6","volume":"44","author":"A Jain","year":"2025","unstructured":"Jain A, Barge A, Parris CN. Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms. Oncogene. 2025;44:193\u2013207.","journal-title":"Oncogene"},{"key":"8912_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113256","volume":"42","author":"H Kim","year":"2023","unstructured":"Kim H, Aliar K, Tharmapalan P, McCloskey CW, Kuttanamkuzhi A, Gr\u00fcnwald BT, et al. Differential DNA damage repair and PARP inhibitor vulnerability of the mammary epithelial lineages. Cell Rep. 2023;42:113256.","journal-title":"Cell Rep"},{"key":"8912_CR50","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41571-024-00939-2","volume":"21","author":"AG Waks","year":"2024","unstructured":"Waks AG, Mart\u00ednez-S\u00e1ez O, Tarantino P, Braso-Maristany F, Pascual T, Cort\u00e9s J, et al. Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance. Nat Rev Clin Oncol. 2024;21:818\u201332.","journal-title":"Nat Rev Clin Oncol"},{"key":"8912_CR51","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/mc.23175","volume":"59","author":"Y Deng","year":"2020","unstructured":"Deng Y, Guo W, Xu N, Li F, Li J. CtBP1 transactivates RAD51 and confers cisplatin resistance to breast cancer cells. Mol Carcinog. 2020;59:512\u20139.","journal-title":"Mol Carcinog"},{"key":"8912_CR52","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cellsig.2018.09.010","volume":"53","author":"G Liu","year":"2019","unstructured":"Liu G, Yu M, Wu B, Guo S, Huang X, Zhou F, et al. Jab1\/Cops5 contributes to chemoresistance in breast cancer by regulating Rad51. Cell Signal. 2019;53:39\u201348.","journal-title":"Cell Signal"},{"key":"8912_CR53","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1002\/1878-0261.13448","volume":"17","author":"L Koob","year":"2023","unstructured":"Koob L, Friskes A, van Bergen L, Feringa FM, van den Broek B, Koeleman ES, et al. MND1 enables homologous recombination in somatic cells primarily outside the context of replication. Mol Oncol. 2023;17:1192\u2013211.","journal-title":"Mol Oncol"},{"key":"8912_CR54","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1146\/annurev.biochem.77.061306.125255","volume":"77","author":"J San Filippo","year":"2008","unstructured":"San Filippo J, Sung P, Klein H. Mechanism of eukaryotic homologous recombination. Annu Rev Biochem. 2008;77:229\u201357.","journal-title":"Annu Rev Biochem"},{"key":"8912_CR55","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70083","volume":"6","author":"Y Meng","year":"2025","unstructured":"Meng Y, Li S, Lu DS, Chen X, Li L, Duan YF, et al. Salt-inducible kinase 2 confers radioresistance in colorectal cancer by facilitating homologous recombination repair. MedComm. 2025;6:e70083.","journal-title":"MedComm"},{"key":"8912_CR56","doi-asserted-by":"publisher","first-page":"6130","DOI":"10.7150\/ijbs.100833","volume":"20","author":"M Li","year":"2024","unstructured":"Li M, Wei J, Xue C, Chen S, Zhou X, Zheng L, et al. BRD7 enhances the radiosensitivity of nasopharyngeal carcinoma cells by negatively regulating USP5\/METTL3 axis-mediated homologous recombination repair. Int J Biol Sci. 2024;20:6130\u201345.","journal-title":"Int J Biol Sci"},{"key":"8912_CR57","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1093\/nar\/gkv259","volume":"43","author":"W Zhao","year":"2015","unstructured":"Zhao W, Sung P. Significance of ligand interactions involving Hop2-Mnd1 and the RAD51 and DMC1 recombinases in homologous DNA repair and XX ovarian dysgenesis. Nucleic Acids Res. 2015;43:4055\u201366.","journal-title":"Nucleic Acids Res"},{"key":"8912_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-92925-6","volume":"15","author":"M Gao","year":"2025","unstructured":"Gao M, Wu Y, Zhang L, Zhou Y, Liu H, Zhang W, et al. YTHDC1 negatively regulates UBE3A to influence RAD51 ubiquitination and inhibit apoptosis in colorectal cancer cells. Sci Rep. 2025;15:8857.","journal-title":"Sci Rep"},{"key":"8912_CR59","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1016\/j.molcel.2023.06.031","volume":"83","author":"O Belan","year":"2023","unstructured":"Belan O, Greenhough L, Kuhlen L, Anand R, Kaczmarczyk A, Gruszka DT, et al. Visualization of direct and diffusion-assisted RAD51 nucleation by full-length human BRCA2 protein. Mol Cell. 2023;83:2925\u201340.e8.","journal-title":"Mol Cell"},{"key":"8912_CR60","doi-asserted-by":"publisher","first-page":"7155","DOI":"10.1073\/pnas.0811159106","volume":"106","author":"SM Sy","year":"2009","unstructured":"Sy SM, Huen MS, Chen J. PALB2 is an integral component of the BRCA complex required for homologous recombination repair. Proc Natl Acad Sci USA. 2009;106:7155\u201360.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8912_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05443-w","volume":"22","author":"Y Xiong","year":"2024","unstructured":"Xiong Y, Shi L, Li L, Yang W, Zhang H, Zhao X, et al. CDCA5 accelerates progression of breast cancer by promoting the binding of E2F1 and FOXM1. J Transl Med. 2024;22:639.","journal-title":"J Transl Med"},{"key":"8912_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-021-00347-6","volume":"10","author":"C Ashok","year":"2021","unstructured":"Ashok C, Ahuja N, Natua S, Mishra J, Samaiya A, Shukla S. E2F1 and epigenetic modifiers orchestrate breast cancer progression by regulating oxygen-dependent ESRP1 expression. Oncogenesis. 2021;10:58.","journal-title":"Oncogenesis"},{"key":"8912_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01183-9","volume":"19","author":"X Zheng","year":"2020","unstructured":"Zheng X, Huang M, Xing L, Yang R, Wang X, Jiang R, et al. The circRNA circSEPT9 mediated by E2F1 and EIF4A3 facilitates the carcinogenesis and development of triple-negative breast cancer. Mol Cancer. 2020;19:73.","journal-title":"Mol Cancer"},{"key":"8912_CR64","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.4161\/15384101.2014.985031","volume":"14","author":"DS Castillo","year":"2015","unstructured":"Castillo DS, Campalans A, Belluscio LM, Carcagno AL, Radicella JP, C\u00e1nepa ET, et al. E2F1 and E2F2 induction in response to DNA damage preserves genomic stability in neuronal cells. Cell Cycle. 2015;14:1300\u201314.","journal-title":"Cell Cycle"},{"key":"8912_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-019-0307-2","volume":"51","author":"EH Choi","year":"2019","unstructured":"Choi EH, Kim KP. E2F1 facilitates DNA break repair by localizing to break sites and enhancing the expression of homologous recombination factors. Exp Mol Med. 2019;51:1\u201312.","journal-title":"Exp Mol Med"},{"key":"8912_CR66","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1146\/annurev-biochem-060713-035513","volume":"83","author":"L Shen","year":"2014","unstructured":"Shen L, Song CX, He C, Zhang Y. Mechanism and function of oxidative reversal of DNA and RNA methylation. Annu Rev Biochem. 2014;83:585\u2013614.","journal-title":"Annu Rev Biochem"},{"key":"8912_CR67","first-page":"1833","volume":"15","author":"WC Lin","year":"2001","unstructured":"Lin WC, Lin FT, Nevins JR. Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation. Genes Dev. 2001;15:1833\u201344.","journal-title":"Genes Dev"},{"key":"8912_CR68","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.4161\/cc.28605","volume":"13","author":"YQ Jin","year":"2014","unstructured":"Jin YQ, An GS, Ni JH, Li SY, Jia HT. ATM-dependent E2F1 accumulation in the nucleolus is an indicator of ribosomal stress in early response to DNA damage. Cell Cycle. 2014;13:1627\u201338.","journal-title":"Cell Cycle"},{"key":"8912_CR69","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/S2215-0366(19)30520-6","volume":"7","author":"S Luza","year":"2020","unstructured":"Luza S, Opazo CM, Bousman CA, Pantelis C, Bush AI, Everall IP. The ubiquitin proteasome system and schizophrenia. Lancet Psychiatry. 2020;7:528\u201337.","journal-title":"Lancet Psychiatry"},{"key":"8912_CR70","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-023-01480-x","volume":"8","author":"J Yang","year":"2023","unstructured":"Yang J, Xu J, Wang W, Zhang B, Yu X, Shi S. Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets. Signal Transduct Target Ther. 2023;8:210.","journal-title":"Signal Transduct Target Ther"},{"key":"8912_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2024.108640","volume":"258","author":"AV Lee","year":"2024","unstructured":"Lee AV, Nestler KA, Chiappinelli KB. Therapeutic targeting of DNA methylation alterations in cancer. Pharm Ther. 2024;258:108640.","journal-title":"Pharm Ther"},{"key":"8912_CR72","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1007\/s00262-021-03064-6","volume":"71","author":"H Triki","year":"2022","unstructured":"Triki H, Declerck K, Charfi S, Ben Kridis W, Chaabane K, Ben Halima S, et al. Immune checkpoint CD155 promoter methylation profiling reveals cancer-associated behaviors within breast neoplasia. Cancer Immunol Immunother. 2022;71:1139\u201355.","journal-title":"Cancer Immunol Immunother"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08912-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08912-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08912-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T03:54:41Z","timestamp":1786074881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08912-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8912"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08912-w","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"21 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"699"}}